Progyny, Inc. (NASDAQ: PGNY) has seen its price target raised from $23.00 to $25.00 by analysts at JPMorgan Chase & Co., as reported on the morning of July 8, 2023. The brokerage maintains a neutral rating on the stock, reflecting cautious optimism amid various market evaluations.
Several other research institutions have also weighed in on Progyny’s performance. Leerink Partners upgraded its rating from “hold” to “strong-buy” on the same day, while Raymond James Financial set an ambitious price target of $28.00 on August 8, 2023. In another positive note, Canaccord Genuity Group adjusted its target to $23.00 from $21.00, maintaining a “hold” rating. Additionally, Cantor Fitzgerald reaffirmed its “overweight” rating, raising its target from $26.00 to $28.00. Meanwhile, Wall Street Zen upgraded its rating from “hold” to “buy” on July 26, 2023. Overall, one analyst has issued a “strong buy” rating, six have given a “buy” rating, and four have assigned a “hold” rating, resulting in a consensus rating of “Moderate Buy” with an average target price of $25.30, according to data from MarketBeat.
Progyny’s Market Performance and Earnings Report
On August 7, 2023, Progyny announced its quarterly earnings, reporting earnings per share (EPS) of $0.19. This figure fell short of the consensus estimate of $0.42 by $0.23. The company generated revenue of $332.87 million for the quarter, surpassing analysts’ expectations of $315.70 million and reflecting a 9.5% increase year-over-year.
Progyny’s stock opened at $22.64 on August 8, 2023. Over the past 12 months, shares have fluctuated between a low of $13.39 and a high of $26.76. The company’s market capitalization currently stands at $1.95 billion, with a price-to-earnings (PE) ratio of 38.37 and a price-to-earnings-growth (PEG) ratio of 1.89. Its 50-day moving average is $22.62, while the two-hundred-day moving average is $22.18.
Looking ahead, Progyny has set its guidance for Q3 2025 at an EPS range of $1.700 to $1.780. Analysts currently forecast an average EPS of $0.60 for the current fiscal year.
Insider Trading and Institutional Investments
In recent insider trading activity, Director Kevin K. Gordon sold 2,500 shares on August 11, 2023, at an average price of $22.04, totaling $55,100. Following this transaction, Gordon retained 12,501 shares valued at approximately $275,522.04, marking a 16.67% reduction in his ownership. Another director, Cheryl Scott, sold 2,675 shares on June 11, 2023, at an average price of $22.07, amounting to $59,037.25, which represented a 15.93% decrease in her position.
Overall, corporate insiders own approximately 9.40% of Progyny’s stock. Institutional investors have shown significant interest, with several hedge funds adjusting their stakes in the company. Notably, D. E. Shaw & Co. Inc. purchased a new stake worth $11,265,000 in the fourth quarter, while BNP Paribas Financial Markets acquired a stake valued at $10,557,000 during the same period. Other notable investors include Nuveen LLC, which invested $13,645,000 in the first quarter, and Voloridge Investment Management LLC, which increased its stake by 85.5% in the fourth quarter. Collectively, institutional investors hold approximately 94.93% of Progyny’s shares.
Progyny specializes in benefits management, focusing on fertility and family building solutions in the United States. Its offerings include differentiated benefits plan designs, personalized member support services, and access to a selective network of fertility specialists, positioning the company as a significant player in the healthcare sector.
